The company’s profit growth is due to “sales growth”.
Zentiva exceeded the RON100 million threshold in domestic sales and achieved external sales of RON123 million in the first three months of 2023, mostly goods delivered to the Czech Republic.
Its raw material costs grew by 17% on the year in the first three months of 2023, of which raw materials account for over half of the total weight of expenses.
In 2005, the former pharma plant Sicomed Bucuresti was acquired by Zentiva Group based in Prague, Czech Republic and took over the name under which it continues to operates at present. In 2009, following an international transaction, Zentiva reached into the portfolio of France’s Sanofi, and in 2018, investment fund Advent International became the majority shareholder of the pharmaceutical producer.
Zentiva S.A is listed on the Bucharest Stock Exchange and has a market capitalization of RON1.39 billion. The company is 95.9% held by Zentiva Group.